metformin has been researched along with Carcinoma, Papillary in 6 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin displays both direct and indirect anti-tumor effects." | 1.42 | Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. ( Chiovato, L; Coperchini, F; Magri, F; Pignatti, P; Rotondi, M, 2015) |
| "Metformin inhibits thyroid cancer cell growth." | 1.42 | Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. ( Bikas, A; Boyle, L; Burman, KD; Costello, J; Hoperia, V; Jensen, K; Klubo-Gwiezdzinska, J; Larin, O; McDaniel, D; Patel, A; Vasko, V; Wartofsky, L, 2015) |
| "Oral metformin treatment via drinking water significantly delayed tumor growth in both tumor development model and established tumor models." | 1.40 | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. ( Cho, SW; Han, SK; Kim, YA; Oh, BC; Park, DJ; Park, YJ; Sun, HJ; Yi, KH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, LR | 1 |
| Wang, X | 1 |
| Hu, K | 1 |
| Li, S | 1 |
| Xiong, YJ | 1 |
| Li, M | 1 |
| Tang, H | 1 |
| Liu, AD | 1 |
| Song, XD | 1 |
| Insin, P | 1 |
| Prueksaritanond, N | 1 |
| Mousavi, Z | 1 |
| Dourandish, L | 1 |
| Rokni, H | 1 |
| Sadeghi, R | 1 |
| Rasoul Zakavi, S | 1 |
| Cho, SW | 1 |
| Yi, KH | 1 |
| Han, SK | 1 |
| Sun, HJ | 1 |
| Kim, YA | 1 |
| Oh, BC | 1 |
| Park, YJ | 1 |
| Park, DJ | 1 |
| Rotondi, M | 1 |
| Coperchini, F | 1 |
| Pignatti, P | 1 |
| Magri, F | 1 |
| Chiovato, L | 1 |
| Bikas, A | 1 |
| Jensen, K | 1 |
| Patel, A | 1 |
| Costello, J | 1 |
| McDaniel, D | 1 |
| Klubo-Gwiezdzinska, J | 1 |
| Larin, O | 1 |
| Hoperia, V | 1 |
| Burman, KD | 1 |
| Boyle, L | 1 |
| Wartofsky, L | 1 |
| Vasko, V | 1 |
1 trial available for metformin and Carcinoma, Papillary
| Article | Year |
|---|---|
Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Body Weight; Carcinoma, Papillary; Dose-Response Relationship, Dr | 2014 |
5 other studies available for metformin and Carcinoma, Papillary
| Article | Year |
|---|---|
[Effects of metformin on papillary thyroid carcinoma in nude rats model].
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferatio | 2018 |
Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Diabetes Mellitus, Typ | 2018 |
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cells | 2014 |
Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Cell Death; Cell Proliferation; Cells, Cultu | 2015 |
Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.
Topics: Adenocarcinoma, Follicular; AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Papillary; Carrier | 2015 |